US drugs board approves GSK's swine flu vaccine
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Glaxosmithkline received a further fillip to its growing swine flu vaccine sales yesterday when the Food and Drug Administration, the regulatory body in the United States, approved the group's treatment.
The nod paves the way for GSK to ship the 7.6 million doses of vaccine the US government has ordered.
The approval is subject to GSK providing further information about an outside contractor that fills the vials for the company, but GSK confirmed yesterday that it expects to provide the vaccine to the US by the end of the year.
A spokesperson for the group refused to comment, however, on how much the US government is paying for each dose, or, if as with the UK Government, the US is receiving a discount. GSK has disclosed that it is charging clients based on a sliding scale, from €7 a dose for developed countries, down to providing the World Health Organisation with 50 million free doses.
GSK's deal with the US is small relative to others it has secured. In the UK the group has agreed to share the supply of about 140 million doses with the US manufacturer Baxter. GSK has so far refused to comment on how the contract with the Government is split between the two companies.
The US deal is for GSK's unadjuvanted vaccine, a different treatment to Pandemrix, which contains an adjuvant – an added chemical that boosts the vaccine's efficacy – and which is largely being used in the UK. Last month, the group's chief executive, Andrew Witty, conceded that GSK would only be a "bit-part player in the US flu scenario". Nonetheless, GSK has taken worldwide orders for more than 440 million doses of Pandemrix.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments